We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
Ford
F
$55.3B
| $672K | ﹤0.01% |
61,915
-8,487
| -12% | -$86.4K |
|
1252
Perspective Therapeutics
CATX
$355M
| $671K | ﹤0.01% |
195,080
+60,019
| +44% | +$158K |
|
1253
Ethan Allen Interiors
ETD
$597M
| $669K | ﹤0.01% |
24,004
+62
| +0.3% | +$1.68K |
|
1254
Chemed
CHE
$6.84B
| $667K | ﹤0.01% |
1,369
-53
| -4% | -$30.2K |
|
1255
Viking Therapeutics
VKTX
$3.75B
| $664K | ﹤0.01% |
+25,072
| New | +$660K |
|
|
SEZL
1256
Sezzle
SEZL
$4.18B
| $664K | ﹤0.01% |
3,705
+3,237
| +692% | +$287K |
|
1257
Genpact
G
$6.39B
| $662K | ﹤0.01% |
15,037
-197
| -1% | -$8.92K |
|
1258
Nomad Foods
NOMD
$1.66B
| $662K | ﹤0.01% |
38,949
-10,519
| -21% | -$193K |
|
1259
e.l.f. Beauty
ELF
$6.14B
| $657K | ﹤0.01% |
5,277
-144,649
| -96% | -$12.3M |
|
1260
Rexford Industrial Realty
REXR
$8.28B
| $656K | ﹤0.01% |
18,442
+145
| +0.8% | +$5.06K |
|
1261
Alkermes
ALKS
$7.95B
| $653K | ﹤0.01% |
22,814
-56,776
| -71% | -$1.69M |
|
1262
Entrada Therapeutics
TRDA
$273M
| $650K | ﹤0.01% |
96,686
-2,034
| -2% | -$16.4K |
|
1263
Badger Meter
BMI
$3.93B
| $649K | ﹤0.01% |
2,648
-39
| -1% | -$8.84K |
|
|
ASIC
1264
Ategrity Specialty Insurance
ASIC
$1.27B
| $646K | ﹤0.01% |
+30,000
| New | +$687K |
|
1265
Morningstar
MORN
$8.16B
| $643K | ﹤0.01% |
2,048
-67
| -3% | -$19.8K |
|
1266
Rambus
RMBS
$9.3B
| $642K | ﹤0.01% |
10,027
-69
| -0.7% | -$3.7K |
|
|
VISN
1267
Vistance Networks Inc
VISN
$1.4B
| $639K | ﹤0.01% |
77,216
-585,067
| -88% | -$3.06M |
|
1268
Universal Display
OLED
$3.81B
| $637K | ﹤0.01% |
4,126
-54
| -1% | -$7.56K |
|
1269
PDF Solutions
PDFS
$1.89B
| $636K | ﹤0.01% |
29,735
+14,581
| +96% | +$276K |
|
|
SKX
1270
DELISTED
Skechers
SKX
| $634K | ﹤0.01% |
10,046
-2,415
| -19% | -$139K |
|
1271
CryoPort
CYRX
$815M
| $634K | ﹤0.01% |
84,937
+59,446
| +233% | +$369K |
|
1272
Carrier Global
CARR
$48.5B
| $632K | ﹤0.01% |
8,639
+6,677
| +340% | +$453K |
|
1273
Blackbaud
BLKB
$2.21B
| $632K | ﹤0.01% |
9,837
-8,419
| -46% | -$526K |
|
1274
Aveanna Healthcare
AVAH
$2.91B
| $631K | ﹤0.01% |
120,594
+32,679
| +37% | +$166K |
|
1275
Lattice Semiconductor
LSCC
$16.2B
| $630K | ﹤0.01% |
12,853
-253
| -2% | -$12.1K |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.